| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/06/1996 | EP0699437A1 Pharmaceutical preparations containing polyunsaturated fatty acids, their esters or salts, together with antioxidant vitamins or provitamins |
| 03/06/1996 | EP0699236A1 Purified mammalian flt3 ligands and agonists and antagonists thereof |
| 03/06/1996 | EP0699208A1 Novel peptide nucleic acids |
| 03/06/1996 | EP0699204A1 Use of indolocarbazole derivatives to treat a pathological condition of the prostate |
| 03/06/1996 | EP0699196A1 Carbazole derivatives with 17,20-lyase-inhibiting activity |
| 03/06/1996 | EP0699191A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 03/06/1996 | EP0699070A1 Aurintricarboxylic acid fractions and analogues with anti-angiogenic activity and methods of use |
| 03/06/1996 | EP0416033B1 Macrocyclic chelates and methods of use thereof |
| 03/06/1996 | EP0395653B1 Synovial phospholipases |
| 03/06/1996 | EP0362259B1 Method of producing cystatin c or modifications hereof and dna-sequence for use when carrying out the method |
| 03/06/1996 | CN1118166A Farnesyl: protein transferase inhibitors as anticancer agents |
| 03/06/1996 | CN1118140A Oligonucleotides modified to improve stability at ACID pH |
| 03/06/1996 | CN1031192C 3'-deamino-4'-deoxy-4'-amino-8-fluoroan-thracyclines and processes for their preparation |
| 03/06/1996 | CA2157531A1 Htfiiia gene |
| 03/05/1996 | US5496946 Production of pyrrolopyrimidines and intermediates therefor |
| 03/05/1996 | US5496846 Taxol treatment of breast cancer |
| 03/05/1996 | US5496813 Spontaneously dispersible concentrates and aqueous microemulsions with steryl retinates having anti-tumor activity |
| 03/05/1996 | US5496809 Of water, 8-n-(diethylaminoethyl)rebeccamycin and a pharmaceutically acceptable acid |
| 03/05/1996 | US5496808 Mono and bis alkylamino-anthracyclines |
| 03/05/1996 | US5496731 Anti-oncogenes |
| 03/05/1996 | US5496556 Administering a steroid reductase inhibiting compound, an androstene derivative |
| 03/01/1996 | CA2157156A1 New tetrahydropyranic compounds, process for their preparation and pharmaceutical composition containing them |
| 03/01/1996 | CA2156959A1 Ortho-substituted benzoic acid derivates |
| 02/29/1996 | WO1996006176A1 Functional modified hsv1-tk |
| 02/29/1996 | WO1996006169A1 Human chemokine beta-9 |
| 02/29/1996 | WO1996006168A2 Retinoblastoma protein-interacting zinc finger proteins |
| 02/29/1996 | WO1996006166A1 Improvements in or relating to binding proteins for recognition of dna |
| 02/29/1996 | WO1996006116A1 Immunoconjugates comprising tyrosine kinase inhibitors |
| 02/29/1996 | WO1996006114A1 Cytadherence peptides for use in modifying mutual adhesion among eukaryotic cells |
| 02/29/1996 | WO1996006095A1 Endothelin antagonists |
| 02/29/1996 | WO1996005866A2 Live vaccine for the treatment of tumour diseases |
| 02/29/1996 | WO1996005863A1 Compounds, pharmaceutical composition and diagnostic device comprising same and their use |
| 02/29/1996 | WO1996005856A1 Human chemokine polypeptides |
| 02/29/1996 | WO1996005842A1 Intravenous alendronate formulations |
| 02/29/1996 | WO1996005833A1 Methods of inhibiting endometrial cancer |
| 02/29/1996 | WO1996001614A3 Rna component of telomerase |
| 02/29/1996 | DE4431401A1 Lebendvakzine gegen Tumorerkrankungen Live vaccines against tumors |
| 02/29/1996 | DE4430601A1 Zelladhäsions-Peptide zur Modifikation des Haftungsverhaltens eukaryontischer Zellen untereinander Cell adhesion peptides to modify the adhesion behavior of eukaryotic cells between each other |
| 02/29/1996 | CA2517691A1 Endothelin antagonists |
| 02/29/1996 | CA2198234A1 Live vaccine for the treatment of tumour diseases |
| 02/29/1996 | CA2198207A1 Cell adhesion peptides for use in modifying mutual adhesion among eukaryotic cells |
| 02/29/1996 | CA2198206A1 Human chemokine beta-9 |
| 02/29/1996 | CA2198119A1 Methods of inhibiting endometrial cancer |
| 02/29/1996 | CA2197890A1 Retinoblastoma protein-interacting zinc finger proteins |
| 02/29/1996 | CA2197577A1 Immunoconjugates comprising tyrosine kinase inhibitors |
| 02/28/1996 | EP0698611A1 Process for N-acyl-5-fluorocytidine derivatives |
| 02/28/1996 | EP0698108A1 Adenoviral vectors of animal origin and use thereof in gene therapy |
| 02/28/1996 | EP0698094A1 Bmp-11 compositions |
| 02/28/1996 | EP0698087A1 Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer |
| 02/28/1996 | EP0698040A1 Lhrh antagonists |
| 02/28/1996 | EP0698019A1 Novel aromatic nitro compounds and their metabolites useful as anti-viral and anti-tumor agents |
| 02/28/1996 | EP0698015A1 Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
| 02/28/1996 | EP0697889A1 COMBINED TREATMENT OF IRON DEPLETION AND IgG ANTIBODY |
| 02/28/1996 | EP0697885A1 Insulin-like growth factor ii as antitumour agent |
| 02/28/1996 | EP0697880A1 Inhibition of leukocyte adhesion |
| 02/28/1996 | EP0697875A1 Use of modified tall-104 cells to treat cancer and viral diseases |
| 02/28/1996 | EP0697868A1 Methods and compositions using optically pure (+)-zileuton |
| 02/28/1996 | CN1117734A 3'-aziridino-anthracycline derivatives |
| 02/28/1996 | CN1117711A potentiation of temozolomide in human tumour cells |
| 02/27/1996 | US5495021 Benzo[f]quinolinones |
| 02/27/1996 | US5494999 For assaying, purifying or inducing cdw52 antibody |
| 02/27/1996 | US5494924 Therapeutical method for the treatment of dermatoses using O-esters of L-carnitine |
| 02/27/1996 | US5494914 Useful for treatment of diseases whose progress is aided by activation of androgen receptors |
| 02/27/1996 | US5494911 Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
| 02/27/1996 | US5494907 11-β substituted-19-nor steroids |
| 02/27/1996 | US5494905 Vitamin D amide derivatives |
| 02/27/1996 | US5494683 Surface modified anticancer nanoparticles |
| 02/27/1996 | CA2155447A1 Substituted biphenyl isoxazole sulfonamides |
| 02/27/1996 | CA1338083C Ozonides of terpenes and their medical uses |
| 02/22/1996 | WO1996005320A1 Adenovirus comprising a gene coding for glutathion peroxidase |
| 02/22/1996 | WO1996005298A1 Antitumor antisense oligonucleotides |
| 02/22/1996 | WO1996005221A1 Calcitonin receptor |
| 02/22/1996 | WO1996005217A1 Pharmaceutical compositions containing estra-1,3,5(10)-triene derivatives |
| 02/22/1996 | WO1996005211A1 Ganglioside gm3 analog having sialic acid residue fluorinated at the 9-position and intermediate therefor |
| 02/22/1996 | WO1996005196A1 Distamycin a analogues as antitumour or antiviral agents |
| 02/22/1996 | WO1996005194A1 Cyclic benzazepine urea derivatives with aggregation-inhibiting effect |
| 02/22/1996 | WO1996005165A1 Retinoic acid x-receptor ligands |
| 02/22/1996 | WO1996005160A1 Oxidized carotenoids, retinoids and related conjugated polyenes, and derived fractions and compounds useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| 02/22/1996 | WO1996004930A1 Transferrin compositions to alleviate the side effects of cytotoxic drugs |
| 02/22/1996 | WO1996004928A1 Calcitonin gene related peptide receptor |
| 02/22/1996 | WO1996004927A1 NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| 02/22/1996 | WO1996004926A1 TWO NON-CONTIGUOUS REGIONS CONTRIBUTE TO NIDOGEN BINDING TO A SINGLE EGF-LIKE MOTIF OF THE LAMININ η1 CHAIN |
| 02/22/1996 | WO1996004925A1 Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| 02/22/1996 | WO1996004904A1 Pharmaceutically stable oxaliplatinum preparation |
| 02/22/1996 | WO1996004789A1 A method of selectively destroying neoplastic cells |
| 02/22/1996 | DE4429079A1 Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung Cyclic urea derivatives, medicaments containing these compounds and processes for their preparation |
| 02/22/1996 | CA2197789A1 Cyclic urea derivatives, pharmaceutical compositions comprising these compounds and processes for their preparation |
| 02/22/1996 | CA2196678A1 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives |
| 02/22/1996 | CA2196053A1 Two non-contiguous regions contribute to nidogen binding to a single egf-like motif of the laminin .gamma.1 chain |
| 02/22/1996 | CA2173727A1 Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof |
| 02/22/1996 | CA2172629A1 Distamycin a analogues as antitumour or antiviral agents |
| 02/21/1996 | EP0697408A1 1 substituted-phenyl-oxazolidene-2-one derivatives and their use as adhesion-receptor antagonists |
| 02/21/1996 | EP0697022A1 Phosphoramidates useful as antitumor agents |
| 02/21/1996 | EP0614455B1 Vitamin d amide derivatives |
| 02/21/1996 | EP0516785B1 RECOMBINANT ANTIBODIES SPECIFIC FOR TNF alpha |
| 02/21/1996 | CN1117295A Condensed heterocyclic glutamic acid derivatives as antiproliferative agents |
| 02/21/1996 | CN1117045A Substituted bicyclic heteroaroylguanidines, a process for their preparation, their use as a medicament or a diagnostic agent, and a medicament containing them |
| 02/21/1996 | CN1117044A Substituted N-heteroaroaroylguanidin, preparation, pharmaceutical application and medicine containg same |
| 02/21/1996 | CN1031060C Process for preparing esters |
| 02/20/1996 | US5493030 5-substituted derivatives of mycophenolic acid |